ZW-49 Uses, Dosage, Side Effects and more
According to Zymeworks, "ZW49 is a bispecific anti-HER2 ADC that is based on the same antibody framework as ZW25 but armed with a cytotoxic payload." It is being investigated for several indications characterized by HER2 expression including breast and gastric cancers that have progressed or are refractory to existing HER2-targeted therapies, and other HER2 expressing solid tumors.
| Trade Name | ZW-49 |
| Generic | ZW-49 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
